SentoClone AB Report issue

For profit Phase 2
Founded: Stockholm Sweden (2004)
Status: Defunct (2012)

Organization Overview

First Clinical Trial
2009
NCT00991250
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

dacarbazine (dtic-dome) (1 trial)

temozolomide (temodar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Melanoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2